A
74.08
2.22 (3.09%)
| Previous Close | 71.86 |
| Open | 71.86 |
| Volume | 617,614 |
| Avg. Volume (3M) | 583,032 |
| Market Cap | 4,108,395,520 |
| Price / Sales | 67.89 |
| Price / Book | 9.97 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -211.46% |
| Operating Margin (TTM) | -847.56% |
| Diluted EPS (TTM) | -2.99 |
| Quarterly Revenue Growth (YOY) | -79.30% |
| Total Debt/Equity (MRQ) | 12.76% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -114.70 M |
| Levered Free Cash Flow (TTM) | -10.43 M |
| Return on Assets (TTM) | -16.69% |
| Return on Equity (TTM) | -35.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Arcellx, Inc. | Bullish | Bullish |
AIStockmoo Score
2.1
| Analyst Consensus | 3.0 |
| Insider Activity | 1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.10 |
|
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 14.50% |
| % Held by Institutions | 102.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilead Sciences, Inc. | 30 Jun 2025 | 6,720,803 |
| Ra Capital Management, L.P. | 30 Jun 2025 | 3,036,527 |
| Perceptive Advisors Llc | 30 Jun 2025 | 2,478,000 |
| Sr One Capital Management, Lp | 30 Jun 2025 | 2,346,630 |
| Aju Ib Investment Co., Ltd. | 30 Jun 2025 | 1,047,557 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 133.00 (Scotiabank, 79.54%) | Buy |
| Median | 115.00 (55.24%) | |
| Low | 110.00 (Citigroup, 48.49%) | Buy |
| Average | 119.33 (61.08%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 66.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 31 Jul 2025 | 133.00 (79.54%) | Buy | 71.39 |
| Citigroup | 17 Jun 2025 | 110.00 (48.49%) | Buy | 62.88 |
| HC Wainwright & Co. | 16 Jun 2025 | 115.00 (55.24%) | Buy | 64.09 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BEHBAHANI ALI | 72.52 | - | 4,207 | 305,092 |
| Aggregate Net Quantity | 4,207 | |||
| Aggregate Net Value ($) | 305,092 | |||
| Aggregate Avg. Buy ($) | 72.52 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BEHBAHANI ALI | Director | 12 Aug 2025 | Acquired (+) | 1,586 | 72.52 | 115,017 |
| BEHBAHANI ALI | Director | 12 Aug 2025 | Acquired (+) | 2,621 | 72.52 | 190,075 |
| Date | Type | Details |
|---|---|---|
| 07 Aug 2025 | Announcement | Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights |
| 21 May 2025 | Announcement | Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |